Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFRT Plus Immunochemotherapy as Neoadjuvant Treatment for GEJA
NCT07182565Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2025
- Primary completion
- Aug 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Started Nov 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07182565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182565.